In this expert discussion Dr Joshua Bauml and Dr Joshua Sabari speak about the updates from the CHRYSALIS trial and what it means for patients with NSCLC.
Dr Bauml first explains what the CHRYSALIS study was about and then Dr Sabari talks about the updates regarding this trial. They speak of the efficacy of amivantamab as seen from the results of the trial and discuss what it means for the patients.
Dr Bauml says that the results seem to suggest a positive outlook for the patients.
They further discuss other drugs and treatment options currently being used to treat non-small cell lung cancer and their efficacy profiles. In the end, Dr Bauml talks about the future for NSCLC patients with the novel targeted therapies currently emerging.
This programme has been supported by an unrestricted educational grant from Janssen.